PFE Alexander Motola, CFA Alexander Motola, 20131

Pfizer Inc. – Buy PFE is a global pharmaceutical company involved in the research, development and marketing of drugs Alexander Motola, Relevant Facts: - PFE has historically been an aggressive buyer of stock - PFE pays a strong dividend - PFE has been acquisitive Company - 80% GM - 3% Yield - -12% Rev Growth - $206B Mkt Cap

Investment Thesis PFE continues buying back stock through my target horizon of 2017, reducing share count from 7.5B in 2012 to 5.2B in 2017 PFE continues to pay $7B annually in dividends; this coupled with the buyback, will cause dividends to grow from $0.88 in 2012 to $1.36 in 2017 PFE has been trading on its dividend yield, currently 3%; if it can trade at 3% in 2017, that’s $45, or 9% per year in appreciation, plus 3% per year in dividends This represents a solid but unspectacular return, but 25% of the return is paid while you are waiting (dividends), and the data to track the progress of thesis is easily available Alexander Motola, 20133

Investment Thesis Additional Upside More cash devoted to buybacks or dividends Return to revenue growth sooner than expected PFE could trade closer to its historical yield of 2.25% Alexander Motola, Risks Big acquisition Cash flow declines Management changes focus from returning cash to shareholders Underinvestment in R&D Recommendation Buy 1.5% PFE, hold until 2017; re-evaluate at the target price

What I thought I knew PFE is negative growth Patent cliff represents a substantial issue and has depressed the multiple for a long time Most/Many investors own it for the dividend Alexander Motola, 20135

PFE – First Steps PFE Website ◦ Conference presentation ◦ Transcript ◦ Annual Reports Started Income Statement (Historical, Annual) Need Yahoo! Finance for Prices going back to 2003 (High and Low) Alexander Motola, 20136

PFE – Second Step Calculate valuation ◦ P/E on current year ◦ P/E one year (A) ahead and two years ◦ P/S ◦ Dividend Yield What I’ve learned (new) ◦ Acquisitions are a big part of the story ◦ WYE particularly important ◦ Accounting isn’t completely clean ◦ Dividend was cut in 2009 Alexander Motola, 20137

PFE – Third Step Analyze What I Have ◦ Dividend bias appears confirmed ◦ Investors discounted the dividend cut in 2009 ◦ Share Count reduction is significant ◦ Is it possible to return $20B to investors each year (33% dividends, 67% buybacks)? Can PFE afford it?  Cash generation analysis Look at YTD performance and filing Enhance model w/ CFO presentation Alexander Motola, 20138

PFE Adjusted Model Forecast ◦ Based on CFO’s comments  Cash generation analysis Look at YTD performance and filing Enhance model w/ CFO presentation Alexander Motola, 20139

PFE 10 Wish List at this point: Valuation history on forward estimates Would love to get historical data on the drugs individually (I’d ideally pull it from a sell side model and then review it for accuracy) Bloomberg “CACS” function, which allows you to analyze acquisition timing and amounts Analyst Reports A second monitor!

PFE CFO’s comments on the Morgan Stanley Healthcare Conference: “If you look at our revenue and you look at the rhythm of our revenue in terms of what our revenues are doing, over the last few years our revenues have been declining. And take out the divestments that we've been doing. If you normalize, our revenues have been declining. They've been declining because of patent expirations. Last year, we had almost $8 billion, almost $8 billion of patent expirations really being driven by Lipitor in the US and Europe. This year almost $4 billion, and the next couple of years $3 billion to $4 billion a year. So we've got that headwind probably for the next couple of years. So that's a negative. [basis for my declines in revenues through 2017] But if you look at some of the positive factors in our revenue, there are several. So one is we have in-line products, some in particular that are performing very well, products like LYRICA, that continue to perform well. If you look at our emerging markets, our emerging markets continue to grow. Some of our markets, like China, are growing very nicely. Last quarter 15% to 16%, and that's after adjusting for price. So literally up 15% to 16%. And then the other thing now is new products. And as we work our way through this process, it's not just the new products we have but advancing the pipeline, creating more revenue from more new products, and then bolting, supplementing with business development. [Pipeline + Emerging + modest acquisitions should get growth going post 2017, I’ve modeled a small pick up in growth, about 3% per year; given more time, I’d get more granular, and analyze the $500MM and over drugs individually] So when you think about the rhythm of the revenues, we've got headwinds. We're going to have that for the next couple of years, but we've got some positive factors within that that I think are helping the business. I didn't mention Consumer. I could mention some other ones, but those are the big-ticket items.” Alexander Motola,

PFE CFO’s comments on the Morgan Stanley Healthcare Conference: “If you think about what we're doing in share buybacks, this year I've said we'd do the mid-teens billions in buybacks. If you take that plus the dividends we're going to pay out this year, we'll return directly to our shareholders over $20 billion in cash this year, just in terms of some of the things that we've been doing. The intent going forward is to continue to do those kinds of things to mitigate as much of the impact of revenue on the bottom line as we can. And I think our track record has been good, and going forward our intent is to continue to do those things to mitigate as much of it as we can.” Alexander Motola,

What else would I do? Full Cash Flow Statement, Balance Sheet Quarterly Income Statements Model each major drug Talk with sell side analysts and the company, especially focusing on the buybacks and dividends Look at global peer group and see if there’s a better idea or another idea Get extremely granular on the model Read all filings and transcripts Alexander Motola,

PFE: Written Assignment PFE faces several challenges, including revenue declines driven by patent expiry on major drugs, some questionable accounting practices, potential pension issues, and the risk of overly aggressive M&A activity. Patent expiry has crushed PFE’s largest drug, Lipitor. In 2008, Lipitor generated revenues of over $12 billion for PFE, but in the most recent complete year, 2012, Lipitor – now generic in every major market – brought in only 1/3 rd that. Although the magnitude varies by drug, this is an issue PFE continues to face in a material way over the next several years for a variety of drugs, and revenues will continue to decline through Alexander Motola,

PFE: Written Assignment PFE aggregates several “below the line” items, such as interest income and interest expense, in “Other” – which falls into Operating Expenses as they report it. This is unconventional and, in my opinion, inappropriate. PFE also has a relatively low ADA of $374mm USD. The company is owed in excess of $1.2B USD from government/government agencies in Italy, Spain, Portugal, Greece, and Ireland; $274mm of which is past due in excess of one year. Additionally, PFE’s total pension obligations are underfunded by over $10B USD, and their expected return on plan assets varies between 5.9%-8.5%, which are unrealistic assumptions in my view. Alexander Motola,

PFE: Written Assignment My recommendation is based on PFE continuing to grow their dividend. Over the past 10 years, the dividend payment to shareholders declined once, during the financial crisis and in advance of the acquisition of WYE, a major event for PFE. During this period, although the stock price was low (less than half of current prices), buybacks ceased. I think a major acquisition would likely be a negative for shareholders in both the near and long term. PFE has continued to grow dividends and buy back stock in spite of declining revenues. Much of this has been driven by operational improvements, such as improved efficiency of R&D and consolidating the manufacturing footprint globally. Lipitor was such a huge part of revenue (25% of total revenues in 2008) but now no drug is > 10% of revenues, so the single drug risk and patent expiry impact is more limited. Alexander Motola,

PFE: Written Assignment Shares outstanding ended FY12 at 7.5 billion and currently stand at 6.5 billion. I think this number will be billion or less by This reduction in share count supports a strongly improving dividend on the same cash payout (roughly $7 billion USD) over that time period. PFE, 10 years ago, had a dividend yield of approximately 2.25%, but currently trades at a 3%. Just before the dividend reduction, which I believe was anticipated by the market, PFE traded at 8.9% yield, but that was a “one time event”. If PFE trades at a 3% in 2017, there is an opportunity to make a 12% annualized return. If PFE ever returned to a 2.25% yield, the total return to today’s investor would be in excess of 100%. Due to the “market plus” return opportunity, I am recommending a small weight in PFE, 1.5%. This is marginally higher than the benchmark weight of 1.32%. Alexander Motola,